RxDoctor Payments Data

Donna Cashdan, DO

Family Medicine · Sherman Oaks, CANPI 1417957135

Payments from drug & device makers

$8,887in general payments, 2019–2025

Across 471 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$610
  • Bausch Health US, LLC$588
  • Novo Nordisk$522
  • Amgen$411
  • Lilly USA, LLC$410
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,83999%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,887 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$146,961
Medicare patients
269
Services billed
1,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$22,214
JardianceEmpagliflozin21$15,023
BrilintaTicagrelor11$4,885
SynthroidLevothyroxine Sodium27$1,839
ValacyclovirValacyclovir Hcl20$1,463
Estradiol17$1,235
Rosuvastatin Calcium99$1,227
Levothyroxine Sodium148$1,126
Escitalopram Oxalate43$841
Estradiol (Twice Weekly)Estradiol15$677
Zolpidem Tartrate45$672
Zafirlukast11$655
Memantine Hcl15$650
Divalproex Sodium24$628
ProgesteroneProgesterone, Micronized14$614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$522$22,21424 claims
Boehringer IngelheimJardiance$99$15,02321 claims
AstraZenecaBrilinta$400$4,88511 claims
AbbVieSynthroid$2,714$1,83927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Sherman Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →